Allogene Therapeutics Inc
Biotechnology
Allogene Therapeutics Inc (ALLO) Stock News
The latest ALLO headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ISABELLE QUÉMÉNEUR IS APPOINTED AS GROUP CHIEF DIGITAL AND INFORMATION OFFICER OF VALLOUREC AND JOINS THE EXECUTIVE COMMITTEE
Vallourec announces the appointment of Isabelle Quéméneur as Group Chief Digital and Information Officer, effective October 5, 2026. Quéméneur, previously Chief Technology Officer at Danone, joins Vallourec's Executive Committee to lead digital transformation initiatives focused on customer value creation and modernizing team operations in response to cybersecurity and AI challenges.
- GlobeNewswire Inc.·
ISABELLE QUÉMÉNEUR EST NOMMÉE DIRECTRICE DIGITAL & SYSTÈMES D’INFORMATION DE VALLOUREC ET REJOINT LE COMITE EXECUTIF DU GROUPE
Vallourec announces the appointment of Isabelle Quéméneur as Director of Digital & IT Systems, effective October 5, 2026. She joins the Executive Committee and brings extensive experience from her previous role as CTO at Danone, along with a background in technology leadership at major international companies including Société Générale, AXA, and Sanofi.
- GlobeNewswire Inc.·
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients assessed after a second infusion showing complete chimerism. The commercial-ready manufacturing process achieved a 90% success rate. The company remains on track to initiate its Phase 3 ALLOHA-2 study this month.
- GlobeNewswire Inc.·
VALLOUREC AND ULTRA CORPOTECH PVT LTD SIGN A MEMORANDUM OF UNDERSTANDING FOR THE DEPLOYMENT OF ITS VAM® THREADING CAPABILITIES IN INDIA
Vallourec has signed a Memorandum of Understanding with Ultra Corpotech Pvt Ltd to deploy its VAM® threading capabilities in India. The partnership aims to establish localized production of premium tubular solutions for Oilfield Services customers, with implementation planned for late 2026 and commissioning expected in early 2027. This reflects the broader shift of manufacturing activities from North America to the Eastern Hemisphere.
- GlobeNewswire Inc.·
VALLOUREC ET ULTRA CORPOTECH PVT LTD SIGNENT UN PROTOCOLE D’ACCORD POUR LE DÉPLOIEMENT DES TECHNOLOGIES DE FILETAGE VAM® EN INDE
Vallourec has signed a memorandum of understanding with Ultra Corpotech Pvt Ltd to deploy VAM® threading technologies in India. The partnership aims to establish local certified production of premium tubular products, with implementation expected by end of 2026 and operations beginning in early 2027. This strategic collaboration responds to the oil and gas services industry's shift of production capacity toward the Eastern Hemisphere, particularly the Mumbai region.